Next Generation Sequencing Panels for Neonatal Mellitus (NDM) and Maturity-Onset Diabetes of the Young (MODY)

Monogenic diabetes mellitus includes a heterogeneous group of diabetes types that are caused by mutations in single genes. It is estimated that the monogenic forms of diabetes could represent as much as 1–2% of all cases of diabetes mellitus 1. The main phenotypes suggestive of an underlying monogenic cause include neonatal diabetes mellitus (NDM), maturity-onset diabetes of the young (MODY) and very rare diabetes-associated syndromes.

Neonatal Diabetes Mellitus (NDM) is diabetes diagnosed within the first 6 months of life and can be characterized as either permanent (PNDM), requiring lifelong treatment, or transient (TNDM), which typically resolves by 18 months of age. NDM is rare with an incidence of approximately 1:1,000,000-260,000 live births.

Maturity-onset diabetes of the young (MODY) is more common than NDM and usually occurs in children or adolescents but may be mild and not detected until adulthood. It is predicted that MODY accounts for approximately 1-2% of all Diabetes cases with an incidence of approximately 100 cases per million in the UK population.

Approximately thirty genes that are highly expressed in the pancreatic beta-cell have been identified in these monogenic subtypes of diabetes, and many other genes have been implicated in syndromes that often include diabetes. Several etiological mechanisms of beta-cell dysfunction are involved including reduced beta-cell number, failure of glucose sensing and increased destruction of the beta-cell, which result in inadequate secretion despite chronic 2-4.

Our NDM/MODY Panel includes analysis of the 45 genes listed below, as well as analysis for the mitochondrial mutations m.3243A>G, m.8296A>G, and m.14709T>C. NDM/MODY Panel Genes ABCC8 CP GLIS3 IL2RA NEUROG3 SLC2A2 AIRE DNAJC3 GLUD1 INS NKX2 STAT3 AKT2 DUT HADH INSR PAX4 TRMT10A APPL1 EIF2AK3 HNF1A KCNJ11 PCBD1 WFS1 BLK FOXP3 HNF1B KLF11 PDX1 ZBTB20 CDKN1C GATA4 HNF4A LRBA PPP1R15B ZFP57 CEL GATA6 IER3IP1 MNX1 PTF1A CISD2 GCK HADH NEUROD1 RFX6

Gene Inheritance Disease Phenotype and Molecular Genetics ABCC8 [OMIM#600509] AD Spontaneous or autosomal dominant activating mutations in the ABCC8 gene, encoding the SUR1 regulatory subunit of the ATP-sensitive potassium channels found in beta cells, cause both permanent (less often) and transient (more often) neonatal diabetes 5. AIRE [OMIM#607358] AR Mutations in AIRE result in autoimmune polyendocrinopathy syndrome type 1, an autosomal recessive condition characterized by adrenal gland insufficiency, hypoparathyroidism, and chronic mucocutaneous candidiasis; in addition to the cardinal features of APS1, some patients exhibit diabetes mellitus, alopecia, or growth hormone deficiency 6. The first manifestations of the disease occur in childhood with other manifestations appearing progressively. AKT2 AD Missense mutations in the AKT2 gene have been identified in patients with hypoinsulinemic [OMIM#164731] with hemihypertrophy 7 and dyslipidemia and hepatic steatosis 8. APPL1 [OMIM#616511] AD Heterozygous loss of function variants in the APPL1 gene have been described in two families with MODY14 9. BLK [OMIM#191305] AD Heterozygous mutations in the BLK gene cause MODY11 10. CDKN1C AD, A heterozygous mutation in CDKN1C has been identified in one family with early-adulthood-onset [OMIM#600856] imprinted diabetes, intrauterine growth restriction, and short stature. Other heterozygous mutations in CDKN1C are typically associated with IMAGE syndrome, which is not known to be associated with diabetes. The CDKN1C gene is paternally imprinted, meaning only maternal transmission of the mutation results in disease. 11 CEL AD In 2 families with autosomal dominantly inherited diabetes and exocrine pancreas dysfunction, also [OMIM#609812] referred to as MODY8, Raeder et. al (2006) identified frameshift deletions in the variable number of tandem repeats (VNTR) of the carboxyl-ester lipase gene, CEL 12.

dnatesting.uchicago.edu • 773-834-0555 06/19 CISD2 AR Mutations in the CISD2 gene cause Wolfram syndrome-2 13. Onset of diabetes mellitus is typically [OMIM#611507] before age 10 years (age range <1 – 17 years). CP AR Homozygous mutations in the CP gene cause aceruloplasminemia characterized by a triad of [OMIM#117700] retinal degeneration, diabetes mellitus, and neurological symptoms 14. DNAJC3 [OMIM#616192] AR Homozygous mutations in DNAJC3 have been identified individuals with combined cerebellar and peripheral with hearing loss and diabetes mellitus in two different consanguineous families. Age of onset of diabetes ranged from 11 to 18 years of age 15. DUT AR A homozygous mutation in DUT has been described in siblings with early-onset diabetes and bone [OMIM#601266] marrow failure 16. In one sibling, diabetes was diagnosed at age 5 years, in the other it was diagnosed at age 28 years. EIF2AK3 AR Mutations in EIF2AK3 cause Wolcott-Rallison syndrome (WRS) an autosomal recessive disorder [OMIM#604032] characterized by permanent neonatal or early infancy insulin-dependent diabetes. Epiphyseal dysplasia, osteoporosis, and growth retardation develop at a later age. EIF2AK3 encodes a translation-regulating kinase present in many tissues that plays an important role in trafficking of proinsulin through the secretory pathway in beta cells 17. FOXP3 [OMIM#300292] X-linked Mutations in the X-linked gene FOXP3 have been identified in patients with a rare form of neonatal monogenic autoimmune diabetes, enteropathy causing severe diarrhea and malnutrition, severe eczema, and autoimmune disease (IPEX syndrome) 18. Although patients with the classically described syndrome have a severe clinical course usually resulting in death within the first few years of life without stem cell transplant, other patients have a milder phenotype and a few have lived into childhood or beyond 19. GATA4 AD A heterozygous mutation in the GATA4 gene has been identified in a patient with pancreatic [OMIM# 600576] agenesis (a rare cause of neonatal diabetes), white matter changes and multi-organ failure 20. Heterozygous mutations in GATA4 have also been identified in individuals with a variety of heart defects, including atrial septal defects, ventricular septal defects, and tetralogy of Fallot 21. GATA6 [OMIM#601656] AD Heterozygous mutations in the GATA6 gene have been found in patients with patients with pancreatic agenesis (a rare cause of neonatal diabetes) and congenital heart defects 22. Intrafamiliar variability has been reported with regard to both severity of diabetes (ranging from neonatally lethal diabetes to adult-onset diabetes associated with agenesis of the pancreas) and the types of congenital cardiac defects in affected individuals 23. GCK AD or AR Glucokinase (GCK) is a key regulatory enzyme in the pancreatic beta-cell. Heterozygous [OMIM#138079] inactivating mutations in GCK cause a subtype of maturity-onset diabetes of the young (MODY2; OMIM# 125851), characterized by mild hyperglycemia, which is present at birth, but is often only detected later in life 24. Homozygous inactivating GCK mutations result in a more severe phenotype, presenting at birth as permanent neonatal diabetes mellitus (PNDM; OMIM# 606176) 24. Heterozygous activating GCK mutations have been reported that cause hypoglycemia (HI; OMIM# 601820). GLIS3 AR Homozygous mutations in GLIS3, encoding a Krüppel-like zinc finger protein, have been reported [OMIM#610192] in six individuals in three families with a syndrome of neonatal diabetes within the first few days of life, low birth weight, mild facial dysmorphism, and congenital primary 25. GLUD1 [OMIM#138130] AD Heterozygous activating missense mutations in the GLUD1 gene have been identified in patients with and hyperammonemia 26. HADH AR Mutations in HADH have been identified in patients with 3-hydroxyacyl-CoA dehydrogenase [OMIM#601609] deficiency presenting as fulminant hepatic failure 27 and in patients with hyperinsulinemic hypoglycemia (HHF4) 28. The hypoglycemia is present at birth or in the neonatal period. HNF1A AD Heterozygous mutations in the HNF1A (MODY-3) and HNF4A genes (MODY-1) are both [OMIM#142410] and associated with MODY. Overall, HNF1A mutations are the most common cause of MODY, with HNF4A mutations having been described in multiple populations including Caucasian, Asian, and African [OMIM#600281] populations 29. Hyperglycemia in patients with MODY-1 and MODY-3 is progressive overtime, and typically results in the need for treatment with oral medications or insulin. HNF1A encodes a HNF-1α and plays a role in regulation of the insulin gene and genes encoding proteins involved in glucose transport and metabolism 30. The HNF4A gene encodes HNF-4α, an orphan nuclear receptor that regulates expression of HNF-1α 29. HNF1B AD Heterozygous mutations in HNF1B are associated with a distinct form of MODY (MODY-5) that is [OMIM#189907] characterized by renal cysts in addition to diabetes 31. HNF1B encodes a transcription factor HNF- 1β and plays a role in regulation of the insulin gene and genes encoding proteins involved in glucose transport and metabolism 29. IER3IP1 [OMIM#609382] AR Homozygous missense mutations in IER3IP1 have been identified in infants from two unrelated consanguineous families exhibiting a similar phenotype of neonatal diabetes with simplified gyral pattern microcephaly and severe infantile-onset epileptic encephalopathy 32. IL2RA [OMIM147730] AR Biallelic mutations in IL2RA are associated with immunodeficiency-41, an autosomal recessive disorder of immune dysregulation; affected individuals present in infancy with recurrent infections, lymphadenopathy, and variable autoimmune features 33. Caudy et al. reported one individual who presented at 6 weeks with insulin-dependent diabetes mellitus and diarrhea. 34 INS AD Heterozygous mutations in INS are rare cause of MODY10 35. In addition, heterozygous autosomal [OMIM#176730] dominantly inherited mutations in the INS gene are the second most common cause of permanent neonatal diabetes (after mutations in KCNJ11), with diagnosis of diabetes sometimes occurring after 6 months of age 35-37. INSR AD Mutations in the INSR gene cause insulin-resistant diabetes mellitus and acanthosis nigricans 38. [OMIM#147670] KCNJ11 [OMIM#600937] AD Spontaneous or autosomal dominant activating mutations in the KCNJ11 gene, encoding the inwardly rectifying potassium-channel subunit (Kir6.2) of the ATP-sensitive potassium channel

dnatesting.uchicago.edu • 773-834-0555 06/19 expressed at the surface of the pancreatic cause both transient permanent (less often) and permanent (more often) neonatal diabetes 39,40. KLF11 AD Heterozygous mutations in the KLF11 gene cause MODY7 41. [OMIM#603301] LRBA [OMIM#6064553] AR Biallelic loss-of-function mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity; several individuals have presented with neonatal diabetes 34,42. LRBA testing should be considered in patients with diabetes diagnosed before the age of one, particularly if they have additional autoimmunity or are born to consanguineous parents. MNX1 AR Homozygous missense mutations in MNX1 have been identified in individuals with permanent [OMIM#142994] neonatal diabetes mellitus from three different consanguineous families 43,44. All patients exhibited severe intrauterine growth retardation. One patient additionally exhibited sacral agenesis and imperforate anus, which are features of , a condition caused by heterozygous mutations in MNX1 [OMIM#176450]. MT-TL1 (m.3243A>G) Mitochondrial Maternally inherited diabetes and deafness (MIDD) is caused by specific mutations in the MT-TE (m.14709T>C mitochondrial DNA. The most common mitochondrial mutation associated with MIDD is MT-TK (m.8296A>G) m.3243A>G 45. The m.3243A>G mutation is also associated with MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) in some individuals. Other findings in patients with the m.3243A>G mutation include macular retinal dystrophy, short stature, myopathy, and cardiac and renal disease 45. The clinical phenotype is highly variable, even within the same family 46. Other mitochondrial mutations identified in patients with MIDD are m.8296A>G 47 and m.14709T>C 48. The age of diagnosis of diabetes in MIDD ranges from 11 to 68 years 49,50. NEUROD1 AR Heterozygous loss-of-function mutations in NEUROD1 are a very rare cause of MODY 51. Diabetes [OMIM#601724] mellitus caused by heterozygous mutations in NEUROD1 has been reported in three families 52,53 and was subsequently designated as MODY6. More recently, two cases with neonatal diabetes by 2 months of age were described to exhibit cerebellar hypoplasia, developmental delay, sensorineural deafness, and visual impairment. They were found to carry two different homozygous frameshift mutations resulting in a truncated NEUROD1 protein 54. NEUROG3 AR A total of five cases with diabetes and chronic intractable malabsorptive diarrhea that started soon [OMIM#610370] after birth have been reported to have recessive mutations in NEUROG3 55,56. NEUROG3 is a transcription factor involved in the determination of neural precursor cells in the neuroectoderm, it is expressed in endocrine progenitor cells and is required for endocrine cell development in the pancreas and intestine 57. NKX2-2 AD Homozygous nonsense or frameshift mutations have been identified in three individuals with [OMIM#604612] severe defects in insulin secretion and presentation of diabetes at an early age without evidence of exocrine insufficiency. All three patients had intrauterine growth retardation and moderate-to- severe developmental delays 43. PAX4 AD Heterozygous mutations in the PAX4 gene cause MODY9 58. [OMIM#167413] PCBD1 AR Biallelic mutations in PCBD1 are associated with tetrahydrobiopterin (BH4)-deficient [OMIM#126090] hyperphenylalaninemia (HPA), characterized by mild transient hyperphenylalanemia often detected by newborn screening; most affected individuals are asymptomatic but may develop nonautoimmune diabetes mellitus during puberty 59,60. PDX1 AR Mutation in the PDX1 gene is a rare cause of MODY 61. In a consanguineous family in which an [OMIM#600733] infant with pancreatic agenesis was homozygous for a 1-bp deletion in the PDX1 gene, Stoffers et al. (1997) 62 found that members heterozygous for this mutation had early-onset type II diabetes mellitus, which they designated MODY4. PPP1R15B AR Abdulkarim et al., 2015, identified a homozygous missense variant in two siblings from a [OMIM#613257] consanguineous family with insulin-dependent diabetes with onset in adolescence or adulthood, microcephaly, intellectual disabilities and short stature 63. The same missense variant was identified in two Canadian siblings with short stature, microcephaly, and developmental delays 64; however, these siblings were five and three years of age at time of reporting so were under the age of presentation of diabetes in the family reported by Abdulkarim et al. PTF1A AR Homozygous truncating mutations in PTF1A cause a syndrome of congenital diabetes involving [OMIM#607194] flexion contractures of arms and legs, paucity of subcutaneous fat and optic nerve hypoplasia, in addition to complete agenesis of the cerebellum and complete absence of the pancreas 65,66. RFX6 AR Rare patients have been described with a syndrome characterized by diabetes within the first few [OMIM#601346] days of life: pancreatic hypoplasia, intestinal atresia, gall bladder agenesis/ hypoplasia, and congenital diarrhea 67,68. Five out of six such cases were subsequently reported to carry homozygous or compound heterozygous mutations in RFX6, highlighting the role of this transcription factor as a key regulator of beta-cell differentiation 69. SLC2A2 AR Mutations in SLC2A2, encoding the facilitative glucose transporter GLUT2, cause Fanconi-Bickel [OMIM#227810] syndrome (FBS) 70. FBS involves hepatomegaly related to hepatic and renal glycogen accumulation, renal proximal tubular dysfunction, delay of puberty and short stature, hypergalactosemia, and mild fasting hypoglycemia but postprandial hyperglycemia and diabetes or impaired glucose tolerance. Elevated glucose levels have in some cases been detected in patients under 1 year of age and FBS should thus be considered in the differential diagnosis of neonatal diabetes when any characteristic features are present 71. STAT3 [OMIM#102582] AD STAT3 has been found to have a role in maintaining glucose- mediated insulin secretion 72. Heterozygous mutations in this gene are associated with infantile-onset multisystem autoimmune disease-1, which commonly manifests as insulin-dependent diabetes mellitus and autoimmune enteropathy during childhood. Other features include short statures and non-specific dermatitis 73,74. TRMT10A AR Individuals from at least two different consanguineous families with microcephaly, early onset [OMIM#616013] diabetes, and short stature were found to have homozygous mutations in TRMT10A 75,76 Yew et dnatesting.uchicago.edu • 773-834-0555 06/19 al. confirmed the association of this syndrome with mutations in this gene and expanded the phenotype, finding affected individuals with epilepsy and 77 WFS1 AR Homozygous or compound heterozygous mutation in the WFS1 gene cause Wolfram syndrome [OMIM#606201] characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness 78. Several large case series have reported onset of diabetes as the earliest and most consistent feature of Wolfram syndrome, with subsequent development of other clinical features. In vitro studies and animal models suggest that WFS1 down regulates endoplasmic reticulum stress and that a reduction in its activity leads to increased apoptosis in beta cells and other tissues 79. Mutations in WFS1 should be considered in patients with early-onset diabetes mellitus, particularly if they develop optic atrophy, diabetes insipidus, and/or deafness. ZBTB20 [OMIM#606025] AD Mutations in ZBTB20 are associated with Primrose Syndrome, which is characterized by insulin- resistant diabetes generally developed in adulthood, distal muscle wasting, and hearing loss and ectopic calcification of the ears and brain 80 ZFP57 [OMIM#612192] AR Transient neonatal diabetes characterized by severe intrauterine growth restriction and diagnosis of diabetes within days of life is most often related to overexpression of associated paternally imprinted genes at chromosome 6q24 81. This is due to paternal uniparental disomy, a paternally inherited duplication, or a maternal methylation defect, such as from recessive mutations in ZFP57 82. These cases exhibit diabetes that resolves spontaneously within a few months, only to return later in life (usually adolescence).

Test methods: Comprehensive sequence coverage of the coding regions and splice junctions of all genes in this panel is performed. Targets of interests are enriched and prepared for sequencing using the Agilent SureSelect system. Sequencing is performed using Illumina technology and reads are aligned to the reference sequence. Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors. All pathogenic and likely pathogenic variants are confirmed by Sanger sequencing. The technical sensitivity of this test is estimated to be >99% for single nucleotide changes and insertions and deletions of less than 20 bp. Our CNV detection algorithm was developed and its performance determined for the sole purpose of identifying deletions and duplications within the coding region of the gene(s) tested. Partial exonic copy number changes and rearrangements of less than 400 bp may not be detected by this methodology. Regions of high homology and repetitive regions may not be analyzed. This methodology will not detect low level mosaicism, balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype. The sensitivity of our deletion/duplication assay may be reduced when DNA extracted by an outside laboratory is provided.

Neonatal Diabetes/MODY Panel (sequence and deletion/duplication analysis of 45 genes and analysis for mitochondrial mutations m.3243A>G, m.8296A>G, and m.14709T>C) Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube Cost: $3000 CPT codes: 81406 81407 Turn-around time: 8 weeks

Results: Results, along with an interpretive report, are faxed to the referring physician as soon as they are completed. One report will be issued for the entire panel. All abnormal results are reported by telephone.

For more information about our testing options, please visit our website at dnatesting.uchicago.edu or contact us at 773-834-0555.

References: 1. Eide SA, Raeder H, Johansson S, et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med. 2008;25(7):775-781. 2. Philipson L, Ellard S, Hattersley A, et al. Genetic Testing in Diabetes Mellitus: A clinical guide to monogenic diabetes. In: Weiss R, ed. Genetic Diagnosis of Endocrine Disorders. London: Elsevier; 2010. 3. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(4):200-213. 4. Porter JR, Barrett TG. Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of and beta cell failure. J Med Genet. 2005;42(12):893-902. 5. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355(5):456-466. 6. Fierabracci A. in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Syndrome (APECED): A "Rare" Manifestation in a "Rare" Disease. Int J Mol Sci. 2016;17(7). 7. Hussain K, Challis B, Rocha N, et al. An activating mutation of AKT2 and human hypoglycemia. Science. 2011;334(6055):474. 8. Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315-322. 9. Prudente S, Jungtrakoon P, Marucci A, et al. Loss-of-Function Mutations in APPL1 in Familial Diabetes Mellitus. Am J Hum Genet. 2015;97(1):177-185.

dnatesting.uchicago.edu • 773-834-0555 06/19 10. Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106(34):14460-14465. 11. Kerns SL, Guevara-Aguirre J, Andrew S, et al. A novel variant in CDKN1C is associated with intrauterine growth restriction, short stature, and early-adulthood-onset diabetes. J Clin Endocrinol Metab. 2014;99(10):E2117-2122. 12. Raeder H, Johansson S, Holm PI, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006;38(1):54-62. 13. Riggs AC, Bernal-Mizrachi E, Ohsugi M, et al. Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia. 2005;48(11):2313- 2321. 14. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology. 1987;37(5):761-767. 15. Ladiges WC, Knoblaugh SE, Morton JF, et al. Pancreatic beta-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58IPK. Diabetes. 2005;54(4):1074-1081. 16. Dos Santos RS, Daures M, Philippi A, et al. dUTPase (DUT) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure. Diabetes. 2017;66(4):1086-1096. 17. Delépine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000;25(4):406-409. 18. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18-20. 19. Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care. 2009;32(1):111-116. 20. Shaw-Smith C, De Franco E, Lango Allen H, et al. GATA4 mutations are a cause of neonatal and childhood-onset diabetes. Diabetes. 2014;63(8):2888-2894. 21. Garg V, Kathiriya IS, Barnes R, et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003;424(6947):443-447. 22. Balasubramanian M, Shield JP, Acerini CL, et al. Pancreatic hypoplasia presenting with neonatal diabetes mellitus in association with and developmental delay. Am J Med Genet A. 2010;152A(2):340-346. 23. Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Yamaguchi E, Tamagawa N. Dominantly inherited diabetes mellitus caused by GATA6 haploinsufficiency: variable intrafamilial presentation. J Med Genet. 2012;49(10):642-643. 24. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512-1526. 25. Senée V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet. 2006;38(6):682-687. 26. Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338(19):1352-1357. 27. O'Brien L, Rinaldo P, Sims H, et al. Fulminant hepatic failure associated with mutations in the medium and short chain L-3-hydroxyacyl-CoA dehydrogenase gene. J Inherit Metab Dis. 2000(23):127. 28. Molven A, Matre GE, Duran M, et al. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes. 2004;53(1):221-227. 29. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345(13):971-980. 30. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A. 1997;94(24):13209- 13214. 31. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet. 1999;8(11):2001-2008. 32. Poulton CJ, Schot R, Kia SK, et al. Microcephaly with simplified gyration, epilepsy, and infantile diabetes linked to inappropriate apoptosis of neural progenitors. Am J Hum Genet. 2011;89(2):265-276. 33. Goudy K, Aydin D, Barzaghi F, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol. 2013;146(3):248-261. 34. Charbonnier LM, Janssen E, Chou J, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135(1):217-227. 35. Molven A, Ringdal M, Nordbø AM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008;57(4):1131-1135. 36. Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A. 2007;104(38):15040-15044. 37. Edghill EL, Flanagan SE, Patch AM, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes. 2008;57(4):1034-1042. 38. Moller DE, Cohen O, Yamaguchi Y, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes. 1994;43(2):247-255. 39. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium- channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838-1849.

dnatesting.uchicago.edu • 773-834-0555 06/19 40. Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004;53(10):2719-2722. 41. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes- associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005;102(13):4807-4812. 42. Lo B, Zhang K, Lu W, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436-440. 43. Flanagan SE, De Franco E, Lango Allen H, et al. Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man. Cell Metab. 2014;19(1):146-154. 44. Bonnefond A, Vaillant E, Philippe J, et al. Transcription factor gene MNX1 is a novel cause of permanent neonatal diabetes in a consanguineous family. Diabetes Metab. 2013;39(3):276-280. 45. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med. 2008;25(4):383-399. 46. Nesbitt V, Pitceathly RD, Turnbull DM, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84(8):936-938. 47. Kameoka K, Isotani H, Tanaka K, et al. Novel mitochondrial DNA mutation in tRNA(Lys) (8296A-->G) associated with diabetes. Biochem Biophys Res Commun. 1998;245(2):523-527. 48. Mezghani N, Mkaouar-Rebai E, Mnif M, et al. The heteroplasmic m.14709T>C mutation in the tRNA(Glu) gene in two Tunisian families with mitochondrial diabetes. J Diabetes Complications. 2010;24(4):270-277. 49. Oka Y, Katagiri H, Ishihara H, Asano T, Kobayashi T, Kikuchi M. Beta-cell loss and glucose induced signalling defects in diabetes mellitus caused by mitochondrial tRNALeu(UUR) gene mutation. Diabet Med. 1996;13(9 Suppl 6):S98-102. 50. Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med. 2001;134(9 Pt 1):721-728. 51. Wright NM, Metzger DL, Borowitz SM, Clarke WL. Permanent neonatal diabetes mellitus and pancreatic exocrine insufficiency resulting from congenital pancreatic agenesis. Am J Dis Child. 1993;147(6):607-609. 52. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997;15(1):106-110. 53. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of mellitus. Nat Genet. 1999;23(3):323-328. 54. Rubio-Cabezas O, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes. 2010;59(9):2326-2331. 55. Rubio-Cabezas O, Jensen JN, Hodgson MI, et al. Permanent Neonatal Diabetes and Enteric Anendocrinosis Associated With Biallelic Mutations in NEUROG3. Diabetes. 2011;60(4):1349-1353. 56. Pinney SE, Oliver-Krasinski J, Ernst L, et al. Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence. J Clin Endocrinol Metab. 2011;96(7):1960-1965. 57. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med. 2006;355(3):270-280. 58. Plengvidhya N, Kooptiwut S, Songtawee N, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007;92(7):2821-2826. 59. Ferrè S, de Baaij JH, Ferreira P, et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol. 2014;25(3):574-586. 60. Thöny B, Neuheiser F, Kierat L, et al. Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4a-carbinolamine dehydratase and transcriptional coactivator (DCoH). Am J Hum Genet. 1998;62(6):1302-1311. 61. Christesen HB, Jacobsen BB, Odili S, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240-1246. 62. Fajans SS, Bell GI, Paz VP, et al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl Res. 2010;156(1):7-14. 63. Abdulkarim B, Nicolino M, Igoillo-Esteve M, et al. A Missense Mutation in PPP1R15B Causes a Syndrome Including Diabetes, Short Stature, and Microcephaly. Diabetes. 2015;64(11):3951-3962. 64. Kernohan KD, Tétreault M, Liwak-Muir U, et al. Homozygous mutation in the eukaryotic translation initiation factor 2alpha phosphatase gene, PPP1R15B, is associated with severe microcephaly, short stature and intellectual disability. Hum Mol Genet. 2015;24(22):6293-6300. 65. Sellick GS, Barker KT, Stolte-Dijkstra I, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet. 2004;36(12):1301-1305. 66. Hoveyda N, Shield JP, Garrett C, et al. Neonatal diabetes mellitus and cerebellar hypoplasia/agenesis: report of a new recessive syndrome. J Med Genet. 1999;36(9):700-704. 67. Mitchell J, Punthakee Z, Lo B, et al. Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new autosomal recessive syndrome. Diabetologia. 2004;47(12):2160-2167. 68. Chappell L, Gorman S, Campbell F, et al. A further example of a distinctive autosomal recessive syndrome comprising neonatal diabetes mellitus, intestinal atresias and gall bladder agenesis. Am J Med Genet A. 2008;146A(13):1713- 1717. 69. Smith SB, Qu HQ, Taleb N, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature. 2010;463(7282):775-780.

dnatesting.uchicago.edu • 773-834-0555 06/19 70. Santer R, Schneppenheim R, Dombrowski A, Götze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the -type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17(3):324-326. 71. Yoo HW, Shin YL, Seo EJ, Kim GH. Identification of a novel mutation in the GLUT2 gene in a patient with Fanconi- Bickel syndrome presenting with neonatal diabetes mellitus and galactosaemia. Eur J Pediatr. 2002;161(6):351-353. 72. Gorogawa S, Fujitani Y, Kaneto H, et al. Insulin secretory defects and impaired islet architecture in pancreatic beta- cell-specific STAT3 knockout mice. Biochem Biophys Res Commun. 2004;319(4):1159-1170. 73. Flanagan SE, Patch AM, Mackay DJ, et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes. 2007;56(7):1930-1937. 74. Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591-599. 75. Igoillo-Esteve M, Genin A, Lambert N, et al. tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans. PLoS Genet. 2013;9(10):e1003888. 76. Gillis D, Krishnamohan A, Yaacov B, Shaag A, Jackman JE, Elpeleg O. TRMT10A dysfunction is associated with abnormalities in glucose homeostasis, short stature and microcephaly. J Med Genet. 2014;51(9):581-586. 77. Yew TW, McCreight L, Colclough K, Ellard S, Pearson ER. tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy. Diabet Med. 2016;33(9):e21-25. 78. Strom TM, Hörtnagel K, Hofmann S, et al. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet. 1998;7(13):2021-2028. 79. Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet. 2007;81(4):673-683. 80. Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair. Nat Genet. 2009;41(9):1022-1026. 81. Mackay DJ, Temple IK. Transient neonatal diabetes mellitus type 1. Am J Med Genet C Semin Med Genet. 2010;154C(3):335-342. 82. Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet. 2008;40(8):949-951.

dnatesting.uchicago.edu • 773-834-0555 06/19